Richard A. Heyman Sells 817 Shares of Enliven Therapeutics, Inc. (NASDAQ:ELVN) Stock

Enliven Therapeutics, Inc. (NASDAQ:ELVN) Director Richard A. Heyman sold 817 shares of Enliven Therapeutics stock in a transaction on Friday, October 18th. The shares were sold at an average price of $30.00, for a total transaction of $24,510.00. Following the completion of the sale, the director now owns 123,673 shares in the company, valued at $3,710,190. The trade was a 0.00 % decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which is available at this hyperlink.

Enliven Therapeutics Trading Up 0.0 %

Shares of ELVN opened at $28.98 on Friday. The company’s fifty day simple moving average is $24.62 and its 200 day simple moving average is $22.93. Enliven Therapeutics, Inc. has a 1-year low of $9.80 and a 1-year high of $30.03. The company has a market cap of $1.36 billion, a price-to-earnings ratio of -15.02 and a beta of 1.10.

Enliven Therapeutics (NASDAQ:ELVN) last announced its quarterly earnings data on Tuesday, August 13th. The company reported ($0.41) EPS for the quarter, beating analysts’ consensus estimates of ($0.58) by $0.17. As a group, research analysts forecast that Enliven Therapeutics, Inc. will post -1.98 earnings per share for the current year.

Hedge Funds Weigh In On Enliven Therapeutics

Institutional investors have recently bought and sold shares of the business. Quest Partners LLC lifted its position in shares of Enliven Therapeutics by 87.3% in the second quarter. Quest Partners LLC now owns 1,592 shares of the company’s stock valued at $37,000 after buying an additional 742 shares during the last quarter. EntryPoint Capital LLC bought a new stake in Enliven Therapeutics in the 1st quarter valued at $167,000. SG Americas Securities LLC acquired a new stake in Enliven Therapeutics during the 3rd quarter valued at $256,000. The Manufacturers Life Insurance Company acquired a new stake in Enliven Therapeutics during the 2nd quarter valued at $322,000. Finally, Blackstone Inc. bought a new position in Enliven Therapeutics during the first quarter worth $443,000. Institutional investors and hedge funds own 95.08% of the company’s stock.

Analyst Upgrades and Downgrades

Separately, HC Wainwright reaffirmed a “buy” rating and issued a $37.00 target price on shares of Enliven Therapeutics in a research report on Tuesday, October 1st.

Enliven Therapeutics Company Profile

Enliven Therapeutics, Inc, a clinical-stage biopharmaceutical company, focuses on the discovery and development of small molecule inhibitors to help patients with cancer. The company’s lead product candidates comprise ELVN-001, which is being evaluated in a Phase 1 clinical trial in adults with chronic myeloid leukemia; and ELVN-002, a Phase 1 clinical trial in adults with solid tumors with HER2 alterations.